Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$60.95

-0.46 (-0.75%)

, SMMT

Summit Therapeutics

$8.65

-0.414 (-4.57%)

07:08
10/04/16
10/04
07:08
10/04/16
07:08

Sarepta, Summit enter into exclusive license, collaboration agreement

Sarepta Therapeutics (SRPT) and Summit Therapeutics (SMMT) announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States, to Summit's utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy, or DMD. As part of the agreement, Sarepta also obtains an option to license Latin American rights to Summit's utrophin modulator pipeline. Summit retains commercialization rights in all other countries. Utrophin modulation is a potential disease-modifying treatment for all patients with the fatal muscle wasting disease DMD, regardless of their underlying dystrophin gene mutation. Ezutromid is currently in a Phase 2 proof of concept trial called PhaseOut DMD. Under the terms of the agreement, Summit will receive an upfront fee of $40M. In addition, Summit will be eligible for future ezutromid related development, regulatory and sales milestone payments totalling up to $522M, including a $22M milestone upon the first dosing of the last patient in Summit's PhaseOut DMD trial, and escalating royalties ranging from a low to high teens percentage of net sales in the licensed territory.

SRPT

Sarepta

$60.95

-0.46 (-0.75%)

SMMT

Summit Therapeutics

$8.65

-0.414 (-4.57%)

  • 06

    Nov

SRPT Sarepta
$60.95

-0.46 (-0.75%)

09/21/16
LEER
09/21/16
NO CHANGE
LEER
Market Perform
Previous PTAB ruling remains overhang on Sarepta eteplirsen, says Leerink
Leerink analyst Joseph Schwartz notes that Sarepta (SRPT) has announced favorable Patent Trial and Appeal Board of the U.S. Patent and Trademark Office decisions in favor of its exon 51 and 53 composition of matter patent interference cases against BioMarin (BMRN). However, he points out that these rulings are subject to appeal and a previous ruling from the U.S. Patent Trial and Appeal Board, or PTAB, in favor of BioMarin's method of use patent remains an overhang on the commercialization of Sarepta's eteplirsen. The analyst reiterates a Market Perform rating on Sarepta's shares.
09/23/16
PIPR
09/23/16
NO CHANGE
Target $64
PIPR
Overweight
Sarepta stock issuance strengthens balance sheet, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says Sarepta Therapeutics has a strengthened balance sheet after issuing 5.02M shares at a price of $59.75. Further, for its Exondys51 approval, Sarepta gained a Rare Priority Review Voucher that could be sold to further pad the company's cash position, Tenthoff tells investors in an intraday research note. He reiterates an Overweight rating on the shares with a $64 price target. The stock is down 5% to $57.74 in late afternoon trading.
09/28/16
09/28/16
NO CHANGE

Experts 'fairly upbeat' on Sarepta drug, says RBC Capital
After speaking with three neurologists who treat DMD, RBC Capital analyst Simos Simeonidis says that the doctors were "fairly bullish" on Sarepta's DMD treatment, EXONDYS 51. The doctors expect to use the drug "in essentially all eligible patients," according to the analyst. Simeonidis raised the price target on Sarepta to $108 from $83 and keeps an Outperform rating on the stock.
09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
SMMT Summit Therapeutics
$8.65

-0.414 (-4.57%)

02/01/16
ADAM
02/01/16
INITIATION
Target $14
ADAM
Buy
Summit Therapeutics initiated with a Buy at Canaccord
Target $14.
02/01/16
02/01/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Acadia (ACHC) initiated with an Overweight at KeyBanc... Altisource Residential (RESI) initiated with a Neutral at Nomura... Colony Starwood Homes (SFR) initiated with a Buy at Nomura... EyeGate (EYEG) initiated with a Buy at Rodman & Renshaw... Fortinet (FTNT) initiated with an Outperform at Northland... Halozyme (HALO) initiated with a Buy at Canaccord... Lendingtree (TREE) initiated with an Outperform at Northland... Lindblad Expeditions (LIND) initiated with an Outperform at Credit Suisse... Summit Therapeutics (SMMT) initiated with a Buy at Canaccord... VolitionRx (VNRX) initiated with a Buy at Rodman & Renshaw.
06/21/16
JANY
06/21/16
INITIATION
Target $15
JANY
Buy
Summit Therapeutics initiated with a Buy at Janney Capital
Janney Capital analyst Debjit Chattopadhyay started coverage of Summit Therapeutics with a Buy rating and $15 fair value estimate as he believes the company's pre-clinical data has been compelling and that two upcoming data reads should clarify its outlook and provide a catalyst for the stock.
09/16/16
HCWC
09/16/16
INITIATION
Target $26
HCWC
Buy
Summit Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther initiated Summit Therapeutics with a Buy and a $26 price target saying Ezutromid in DMD can potentially generate $1.2B in global sales in FY26.

TODAY'S FREE FLY STORIES

MIK

Michaels

$23.85

-0.46 (-1.89%)

05:29
12/07/16
12/07
05:29
12/07/16
05:29
Downgrade
Michaels rating change  »

Michaels downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$71.97

0.3 (0.42%)

05:28
12/07/16
12/07
05:28
12/07/16
05:28
Downgrade
Kellogg rating change  »

Kellogg downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVI

Navient

$17.03

0.03 (0.18%)

05:28
12/07/16
12/07
05:28
12/07/16
05:28
Initiation
Navient initiated  »

Navient initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSK

Verisk Analytics

$83.04

0.13 (0.16%)

05:25
12/07/16
12/07
05:25
12/07/16
05:25
Initiation
Verisk Analytics initiated  »

Verisk Analytics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

CMCO

Columbus McKinnon

$27.59

1.07 (4.03%)

05:25
12/07/16
12/07
05:25
12/07/16
05:25
Hot Stocks
Columbus McKinnon to acquire STAHL CraneSystems for about $240M »

Columbus McKinnon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLGX

CoreLogic

$37.89

-0.28 (-0.73%)

05:24
12/07/16
12/07
05:24
12/07/16
05:24
Initiation
CoreLogic initiated  »

CoreLogic initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

MGP

MGM Growth

$24.60

-0.18 (-0.73%)

, GLPI

Gaming and Leisure Properties

$30.70

0.24 (0.79%)

05:21
12/07/16
12/07
05:21
12/07/16
05:21
Downgrade
MGM Growth, Gaming and Leisure Properties, Boyd Gaming rating change  »

MGM Growth downgraded to…

MGP

MGM Growth

$24.60

-0.18 (-0.73%)

GLPI

Gaming and Leisure Properties

$30.70

0.24 (0.79%)

BYD

Boyd Gaming

$19.63

0.39 (2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASX

Advanced Semiconductor

$5.38

0.11 (2.09%)

05:20
12/07/16
12/07
05:20
12/07/16
05:20
Hot Stocks
Advanced Semiconductor reports Nov. revenue up 1.3% to $821M »

Reports November ATM net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIA

Acacia Communications

$70.14

1.08 (1.56%)

05:19
12/07/16
12/07
05:19
12/07/16
05:19
Hot Stocks
Acacia Communications establishes EMEA-APAC headquarters in Limerick, Ireland »

Acacia Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.96

-0.01 (-0.01%)

05:18
12/07/16
12/07
05:18
12/07/16
05:18
Hot Stocks
Novartis drug Lucentis receives EU approval in new indication »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$63.85

1.76 (2.83%)

05:18
12/07/16
12/07
05:18
12/07/16
05:18
Recommendations
Western Digital analyst commentary  »

Western Digital price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$12.56

0.12 (0.96%)

05:16
12/07/16
12/07
05:16
12/07/16
05:16
Hot Stocks
Ford reports Nov. China sales up 17% to 124,113 vehicles »

Ford and its joint…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 10

    Jan

MU

Micron

$19.06

0.45 (2.42%)

05:15
12/07/16
12/07
05:15
12/07/16
05:15
Initiation
Micron initiated  »

Micron initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 21

    Dec

ESGR

Enstar Group

$194.15

0.5 (0.26%)

05:12
12/07/16
12/07
05:12
12/07/16
05:12
Hot Stocks
Enstar Group announces reinsurance of QBE Legacy U.S. business »

Enstar Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRUE

TrueCar

$12.44

0.02 (0.16%)

05:10
12/07/16
12/07
05:10
12/07/16
05:10
Recommendations
TrueCar analyst commentary  »

TrueCar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWI

Titan International

$11.68

0.08 (0.69%)

05:10
12/07/16
12/07
05:10
12/07/16
05:10
Hot Stocks
Titan International appoints interim CFO James Froisland to CFO »

The board of Titan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANET

Arista Networks

$93.86

1.11 (1.20%)

, HPE

HP Enterprise

$23.96

-0.25 (-1.03%)

05:08
12/07/16
12/07
05:08
12/07/16
05:08
Recommendations
Arista Networks, HP Enterprise analyst commentary  »

Arista Networks price…

ANET

Arista Networks

$93.86

1.11 (1.20%)

HPE

HP Enterprise

$23.96

-0.25 (-1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

DPSGY

Deutsche Post

$31.62

0.015 (0.05%)

05:03
12/07/16
12/07
05:03
12/07/16
05:03
Upgrade
Deutsche Post rating change  »

Deutsche Post upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLLLY

Delta Lloyd

05:03
12/07/16
12/07
05:03
12/07/16
05:03
Upgrade
Delta Lloyd rating change  »

Delta Lloyd upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSREY

Swiss Re

$23.68

0.195 (0.83%)

05:02
12/07/16
12/07
05:02
12/07/16
05:02
Upgrade
Swiss Re rating change  »

Swiss Re upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZURVY

Zurich Insurance

$26.82

0.365 (1.38%)

05:01
12/07/16
12/07
05:01
12/07/16
05:01
Upgrade
Zurich Insurance rating change  »

Zurich Insurance upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AV

Aviva

$11.86

0.36 (3.13%)

05:00
12/07/16
12/07
05:00
12/07/16
05:00
Upgrade
Aviva rating change  »

Aviva upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHP

BHP Billiton

$38.34

-0.4 (-1.03%)

04:58
12/07/16
12/07
04:58
12/07/16
04:58
Downgrade
BHP Billiton rating change  »

BHP Billiton downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

RIO

Rio Tinto

$39.25

-0.24 (-0.61%)

04:57
12/07/16
12/07
04:57
12/07/16
04:57
Upgrade
Rio Tinto rating change  »

Rio Tinto upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMI

Kinder Morgan

$21.12

-0.34 (-1.58%)

, PAA

Plains All American

$31.38

0.02 (0.06%)

04:55
12/07/16
12/07
04:55
12/07/16
04:55
Conference/Events
Wells Fargo to hold a symposium »

15th Annual Wells Fargo…

KMI

Kinder Morgan

$21.12

-0.34 (-1.58%)

PAA

Plains All American

$31.38

0.02 (0.06%)

AMID

American Midstream Partners

$16.80

1 (6.33%)

NSH

NuStar GP Holdings

$27.30

0.3 (1.11%)

SPGI

S&P Global

$113.57

-0.71 (-0.62%)

MCO

Moody's

$96.91

0.08 (0.08%)

GLP

Global Partners

$15.90

0.05 (0.32%)

BKEP

Blueknight Energy Partners

$6.65

0.15 (2.31%)

TLP

Transmontaigne Partners

$42.34

-0.15 (-0.35%)

D

Dominion

$72.71

-0.77 (-1.05%)

SHLX

Shell Midstream

$27.22

-0.28 (-1.02%)

ENBL

Enable Midstream

$15.66

-0.09 (-0.57%)

DPM

DCP Midstream

$34.91

0.24 (0.69%)

VNOM

Viper Energy

$15.89

-0.11 (-0.69%)

EPD

Enterprise Products

$25.38

-0.17 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 14

    Dec

  • 14

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.